Christian Moser

Summary

Publications

  1. ncbi Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine
    Maria Grazia Cusi
    Virology Section, Department of Molecular Biology, Siena University School of Medicine, Italy
    J Immunol 174:7210-6. 2005
  2. doi Influenza virosomes as a vaccine adjuvant and carrier system
    Christian Moser
    Pevion Biotech AG, CH 3063 Ittigen, Switzerland
    Expert Rev Vaccines 10:437-46. 2011
  3. doi Influenza virosomes as vaccine adjuvant and carrier system
    Christian Moser
    Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH 3063, Switzerland
    Expert Rev Vaccines 12:779-91. 2013
  4. ncbi Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations
    Christian Moser
    Pevion Biotech, Rehhagstrasse 79, 3018 Bern, Switzerland
    Expert Rev Vaccines 6:711-21. 2007
  5. ncbi Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
    Diana Felnerova
    Berna Biotech Ltd, Rehhagstrasse 79, CH 3018, Berne, Switzerland
    Curr Opin Biotechnol 15:518-29. 2004
  6. ncbi Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine
    Rinaldo Zurbriggen
    Pevion Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 2:295-304. 2003
  7. ncbi Influenza virosomes as an efficient system for adjuvanted vaccine delivery
    Reinhard Gluck
    Berna Biotech Ltd, Rehhagstrasse 79, Berne, Switzerland
    Expert Opin Biol Ther 4:1139-45. 2004
  8. ncbi Virosomal adjuvanted antigen delivery systems
    Christian Moser
    Virology, Berna Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 2:189-96. 2003
  9. ncbi Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants
    Véronique Revaz
    Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Antiviral Res 76:75-85. 2007
  10. ncbi Establishment and application of bicistronic classical swine fever virus genomes for foreign gene expression and complementation of E2 deletion mutants
    Peter Stettler
    Institute of Virology and Immunoprophylaxis, CH 3147 Mittelhäusern, Switzerland
    Virus Res 85:173-85. 2002

Collaborators

Detail Information

Publications10

  1. ncbi Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine
    Maria Grazia Cusi
    Virology Section, Department of Molecular Biology, Siena University School of Medicine, Italy
    J Immunol 174:7210-6. 2005
    ....
  2. doi Influenza virosomes as a vaccine adjuvant and carrier system
    Christian Moser
    Pevion Biotech AG, CH 3063 Ittigen, Switzerland
    Expert Rev Vaccines 10:437-46. 2011
    ..The mode of action of virosomes is complex and includes carrier as well as immune-stimulatory functions...
  3. doi Influenza virosomes as vaccine adjuvant and carrier system
    Christian Moser
    Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH 3063, Switzerland
    Expert Rev Vaccines 12:779-91. 2013
    ..The inclusion of additional components to optimize particle assembly, to stabilize the formulations, or to enhance the immunostimulatory properties have further improved and broadened the applicability of the platform. ..
  4. ncbi Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations
    Christian Moser
    Pevion Biotech, Rehhagstrasse 79, 3018 Bern, Switzerland
    Expert Rev Vaccines 6:711-21. 2007
    ..At the same time, the formulation procedure is sufficiently flexible to allow modifications of the composition and structure for the intended use, including the positioning of the antigens of interest...
  5. ncbi Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
    Diana Felnerova
    Berna Biotech Ltd, Rehhagstrasse 79, CH 3018, Berne, Switzerland
    Curr Opin Biotechnol 15:518-29. 2004
    ....
  6. ncbi Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine
    Rinaldo Zurbriggen
    Pevion Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 2:295-304. 2003
    ..This review discusses the nonclinical safety evaluation of Escherichia coli heat-labile toxin as a mucosal adjuvant for an intranasally administered influenza vaccine...
  7. ncbi Influenza virosomes as an efficient system for adjuvanted vaccine delivery
    Reinhard Gluck
    Berna Biotech Ltd, Rehhagstrasse 79, Berne, Switzerland
    Expert Opin Biol Ther 4:1139-45. 2004
    ..Further investigations are ongoing in order to define the full potential of virosomes in both prophylactic and immunotherapeutic applications...
  8. ncbi Virosomal adjuvanted antigen delivery systems
    Christian Moser
    Virology, Berna Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 2:189-96. 2003
    ..The principles of the concept, immunoadjuvant action and application of virosomes in two currently licensed vaccines are detailed, with specific reference to the induction of both humoral and cellular immunity...
  9. ncbi Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants
    Véronique Revaz
    Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Antiviral Res 76:75-85. 2007
    ....
  10. ncbi Establishment and application of bicistronic classical swine fever virus genomes for foreign gene expression and complementation of E2 deletion mutants
    Peter Stettler
    Institute of Virology and Immunoprophylaxis, CH 3147 Mittelhäusern, Switzerland
    Virus Res 85:173-85. 2002
    ..This shows that E2 deletion mutants can be complemented by expression of E2 from a separate cistron...